What is BPC-157? What the studies show

• Human data: limited and early. There are three small pilot studies without a control group and one randomised study published only as a conference abstract. The first controlled study on musculoskeletal tissue has been registered by a university and is planned for 2027.
• Preclinical research: extensive, with dozens of publications, the large majority from a single research group.
• Status: it is not an approved medicine in any country. It is in a transitional regulatory status in the US and is on the WADA Prohibited List.

BPC-157 was first described in 1993 as a 15-amino-acid fragment of a larger protein isolated from gastric juice, "Body Protection Compound" (BPC). Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of about 1,419 Da.

Although it is often called a "natural peptide", the BPC-157 used in research is synthetic: it is made in the laboratory, and it has not been shown that the 15-mer itself circulates freely in the body. In laboratory conditions it has been reported to remain stable in gastric juice, which explains why it was first studied for the gastrointestinal tract.

This is the most important point for anyone reading about BPC-157: human data are very limited. According to a 2026 review, all of it together covers fewer than 30 people in three pilot studies without a control group.

• Lee & Padgett, 2021 — knee pain · 16 people · retrospective chart review · no control group, self-report by telephone
• Lee et al., 2024 — interstitial cystitis · 12 people · open pilot · no placebo, subjective scale
• Lee & Burgess, 2025 — safety markers · 2 people · pilot · 2 people, 3 days of follow-up
• Ruenzi et al., 2005 — ulcerative colitis · 53 people · randomised, placebo-controlled · conference abstract only, no statistically significant difference

What this means. The authors of the pilot studies reported improvement in the symptoms they measured. Without a control group, without blinding and with subjective tools, such studies cannot separate the effect of the substance from placebo or from the natural course. The only randomised study showed no statistically significant difference from placebo, and the FDA judged its available data "inadequate". All three pilot studies come from the same clinical investigator.

What is coming. On ClinicalTrials.gov, the University of Arkansas has registered a randomised, double-blind, placebo-controlled pilot study after rotator cuff repair (NCT07803250), planned to start in 2027. It will be among the first controlled studies on musculoskeletal tissue. The same registry also contains records of doubtful reliability, so we only cite those from recognised institutions.

Most of the BPC-157 literature concerns preclinical models, meaning animal models and cell cultures. These findings show where research is worth looking, not what happens in humans.

Tendons and ligaments. In Achilles tendon injury models, researchers recorded better biomechanical markers, such as load to failure, and better histology than control groups (Staresinic 2003). Similar results were reported in tendon-to-bone detachment models (Krivic 2006) and medial collateral ligament injury models (Cerovecki 2010).

Notably, an independent research group in 2026, in an Achilles tendon model, recorded only numerical and not statistically significant improvements for BPC-157 in total scores (Biçer 2026). It is one of the few studies outside the original group and shows why findings need replication.

Muscle. In models of complete muscle transection, contusion injury and muscle-to-bone detachment, researchers reported better functional and histological recovery (Staresinic 2006; Novinscak 2008; Matek 2025).

Bone and nerve. Findings have been published on the healing of segmental bone defects (Sebecić 1999), on peripheral nerve regeneration (Gjurasin 2010) and on functional markers after spinal cord injury (Perovic 2019).

Gastrointestinal tract. BPC-157 research began with the stomach. There are studies on the healing of intestinal anastomoses (Vuksic 2007) and on models of inflammatory bowel disease (Veljaca 1995).

Three mechanisms appear most often in the literature:

1. Cell migration via FAK–paxillin. In cultured tendon fibroblasts, BPC-157 did not directly increase cell proliferation, but it increased phosphorylation of FAK and paxillin, proteins linked to cell motility (Chang 2011).
2. VEGFR2–Akt–eNOS signalling and nitric oxide. In endothelial cells, BPC-157 increased expression of the VEGFR2 receptor and activated signalling that leads to nitric oxide production (Hsieh 2017; 2020). In isolated segments of human artery, in the laboratory, it relaxed the vessel through nitric oxide (Yildirim 2026). This concerns tissue outside the body, not a study in humans.
3. Growth hormone receptor in tendon. In tendon fibroblasts, expression of the growth hormone receptor increased (Chang 2014). The finding concerns the receptor on the cells and does not show an increase in growth hormone itself.

An honest overview has to say clearly what remains open:

• One group, few replications. More than 80% of BPC-157 publications list members of a single research group as first or senior author (Józwiak 2025). Independent replications are few.
• Research in humans is at an early stage and studies are small. There are no published controlled studies on tendon or muscle.
• Human pharmacokinetics: according to the FDA, no data exist. In preclinical models the half-life is under 30 minutes (He 2022).
• Safety: one toxicology study recorded no serious toxicity (Xu 2020). The FDA, however, reviewing 28-day data, noted signals in blood clotting and in the liver, as well as a lack of carcinogenicity and immunogenicity studies.
• Angiogenesis: an open question. Independent researchers consider the same signalling studied for tissue repair a possible risk in relation to tumours. The original group argues the opposite. There are no human data to settle the question.
• Material quality: the FDA considers BPC-157 not adequately characterised physicochemically. This is why documenting each batch with a purity analysis (COA) matters in research.

Three independent reviews from 2025–2026 reach the same conclusion: BPC-157 should be considered an investigational substance, and preclinical findings have not been confirmed in humans (McGuire 2025; Mateescu 2026; Am J Sports Med 2026).

• Approved medicine: there is no approved product containing BPC-157 in any country, and no monograph in the European, Japanese or International Pharmacopoeia.
• United States: the FDA page (current as of 22 April 2026) lists BPC-157 among substances whose nomination to "Category 2" was withdrawn by the nominators. This is not an approval, and the same page keeps its safety caveats. On 23 July 2026 the PCAC advisory committee voted 8-6 (with one abstention) in favour of adding it to the list of bulk substances for compounding. The vote is non-binding and the FDA's final decision is pending. The correct description is: in a transitional regulatory status.
• Sport: BPC-157 is on the WADA 2026 Prohibited List, in category S0 (non-approved substances).

1. Sikirić P et al. J Physiol Paris 1993. PMID 8298609
2. Staresinic M et al. J Orthop Res 2003. PMID 14554208
3. Krivic A et al. J Orthop Res 2006. PMID 16583442
4. Cerovecki T et al. J Orthop Res 2010. PMID 20225319
5. Biçer et al. Jt Dis Relat Surg 2026. PMID 42542926
6. Chang CH et al. J Appl Physiol 2011. PMID 21030672
7. Chang CH et al. Molecules 2014. PMID 25415472
8. Staresinic M et al. J Orthop Res 2006. PMID 16609979
9. Novinscak T et al. Surg Today 2008. PMID 18668315
10. Matek D et al. Pharmaceutics 2025. PMID 39861766
11. Sebecić B et al. Bone 1999. PMID 10071911
12. Gjurasin M et al. Regul Pept 2010. PMID 19903499
13. Perovic D et al. J Orthop Surg Res 2019. PMID 31266512
14. Vuksic T et al. Surg Today 2007. PMID 17713731
15. Veljaca M et al. J Pharmacol Exp Ther 1995. PMID 7815358
16. Hsieh MJ et al. J Mol Med 2017. PMID 27847966
17. Hsieh MJ et al. Sci Rep 2020. PMID 33051481
18. Yildirim et al. J Clin Med 2026. PMID 42123221
19. Lee E, Padgett B. Altern Ther Health Med 2021. PMID 34324435
20. Lee E et al. Altern Ther Health Med 2024. PMID 39325560
21. Lee E, Burgess K. Altern Ther Health Med 2025. PMID 40131143
22. He L et al. Front Pharmacol 2022. PMID 36588717
23. Xu C et al. Regul Toxicol Pharmacol 2020. PMID 32334036
24. Józwiak M et al. Pharmaceuticals 2025. PMID 41155566
25. McGuire FP et al. Curr Rev Musculoskelet Med 2025. PMID 40789979
26. Mateescu DM et al. Pharmaceutics 2026. PMID 42198317
27. Am J Sports Med 2026. PMID 42578445
28. Vasireddi N et al. HSS J 2025. PMID 40756949
29. FDA, Briefing Document PCAC, BPC-157, 2026 (also includes the data of Ruenzi et al. 2005 on ulcerative colitis, published only as a conference abstract)
30. ClinicalTrials.gov: NCT07803250

This article is an informational overview of published research. It is not medical advice and gives no directions for use, amounts or protocols. Avenor products are supplied strictly for laboratory research and not for human or veterinary use.